



Charles E. Murry, M.D., Ph.D.
Chair of Stem Cell Biology and Regenerative Medicine,
Pathology and Medicine
Director, Eli and Edythe Broad Center for
Regenerative Medicine and Stem Cell Research

## SHORT BIO Charles Murry, M.D., Ph.D., Dr.

Dr. Charles (Chuck) Murry received his bachelor's degree in chemistry from the University of North Dakota, followed by MD-PhD training at Duke University, where he studied myocardial ischemia-reperfusion injury (heart attacks). He did residency training in Pathology at the University of Washington, followed by fellowship training in vascular biology and diagnostic cardiovascular pathology.

Murry completed his 28 years as a professor with tenure in the departments of Laboratory Medicine & Pathology, Bioengineering, and Medicine/Cardiology at the University of Washington. In August 2024, he joined the Keck School of Medicine of USC as the Chair of Stem Cell Biology an Regenerative Medicine and Director of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research.

Murry's research focuses on stem cell biology, with an emphasis on understanding differentiation of the human cardiovascular system and using these cells to study diseases and to regenerate damaged tissues. His group is a world leader in heart regeneration and is working toward a clinical trial using cardiomyocyte therapy.

Apart from running his research group, Dr. Murry was the director of the UW Institute for Stem Cell and Regenerative Medicine. He has served on many local, national and international committees, spoken widely about stem cells and cardiovascular medicine, and he has received numerous awards for teaching and scientific achievement. Dr. Murry previously served on the International Society for Stem Cell Research Board of Directors and currently serves on its Manufacturing, Clinical Translation and Industry Committee.

In addition to his academic work, Murry has worked to promote commercialization of novel cardiovascular therapies. He cofounded BEAT Biotherapeutics, Sana Biotechnology, and most recently a Los Angeles-based startup called StemCardia.

